Cardiac Amyloidosis and Its Impact on the Heart

The heart is the motor in the human body, a relentless muscle that pumps the vital blood to all the organs. Nevertheless, there are uncommon diseases that can weaken its structural integrity, causing deterioration of its functions to a significant level that may not be realised promptly. One such condition is cardiac amyloidosis, often referred to as "stiff heart syndrome."

The condition arises when there is an unusual buildup of proteins in the heart tissue, known as amyloids. These deposits hinder the heart's ability to relax and fill with blood between beats, leading to heart failure. Understanding the specifics of this disease is crucial for timely treatment and improved patient results.

What is Cardiac Amyloidosis?

Cardiac amyloidosis is a disease where abnormal, misfolded proteins accumulate in the heart muscle, causing it to become thick and stiff over time. To understand why this matters, it helps to think of the heart muscle as a sponge, normally flexible and able to expand and contract freely. In cardiac amyloidosis, that sponge becomes gradually filled with rigid, sticky protein fibres that do not belong there, depriving it of its inherent flexibility. Unlike the healthy muscle thickening seen in athletes or people with well-managed high blood pressure, this stiffness is entirely non-functional and progressive.

There are two primary types of this heart disease that clinicians encounter:

• Light Chain Amyloidosis (AL): This type is linked to bone marrow disorders, such as multiple myeloma. In AL amyloidosis, the bone marrow produces abnormal proteins called light chains, which travel through the bloodstream and deposit themselves in various organs, including the heart.
• Transthyretin Amyloidosis (ATTR): This is characterised by the TTR protein, which is synthesised in the liver. It could be hereditary (mutated TTR), which is called wild-type (age-related).

How Amyloidosis Leads to a Stiff Heart Muscle

The central problem in cardiac amyloidosis is that the heart loses its ability to relax properly between beats,  a condition doctors call diastolic dysfunction. Under normal circumstances, the heart muscle stretches and expands to fill with blood before each contraction. This filling phase is just as important as the squeezing phase. When amyloid protein fibres build up in the spaces between the heart muscle cells, the walls of the heart become too stiff and rigid to expand adequately. 

In the early stages of the disease, the heart can often still contract (squeeze) reasonably well, but it simply cannot fill with enough blood in the first place. Over time, this creates a backlog of pressure, fluid backs up into the lungs and accumulates in the rest of the body. This is the mechanism behind the breathlessness, swollen limbs, and persistent fatigue that patients experience.

Recognising the Symptoms of Cardiac Amyloidosis

One of the greatest challenges in managing this disease is that its symptoms often mimic more common cardiovascular issues, such as hypertensive heart disease or standard heart failure. It is quite common that patients are exposed to a progressive worsening of physical ability, and they may attribute this to old age.

Key Indicators of Cardiovascular Primary

The symptoms most pronounced have to do with the inefficiency of the heart to pump. Patients frequently report:

• Shortness of Breath (Dyspnea): It usually happens first during exertion, but then moves on to manifestations of breathlessness during rest or a lying position (orthopnea).
• Peripheral Edoema: Swelling usually develops in the legs, ankles, and feet and is associated with the backup of fluid in the vascular system.
• Fatigue and Lethargy: Patients have a consistent experience of fatigue because the amount of oxygenated blood supply in the body cannot sufficiently circulate throughout the body.
• Arrhythmias: Atrial fibrillation is a prevalent issue, especially in such patients, and it can sometimes cause the patient to experience palpitations or a fluttering feeling within his/her chest.

Systemic and Non-Cardiac Clues

Since amyloidosis is commonly a systemic condition, it may have other "red flag" symptoms outside of the heart that may indicate the diagnosis. As an example, many patients who are later suspected of having the ATTR type of amyloidosis often had carpal tunnel syndrome years before any heart-related symptoms appear. In many cases, this condition affects both wrists and may occur long before the heart starts showing signs of disease. Other signs include:

• Spinal Stenosis: The canal of the spine is narrow, which causes pain in the back or numbness in the legs.
• Bicep Tendon Rupture: Rupture of the tendon, which has no major trauma.
• Neuropathy: The hands and feet may have tingling, numbness or pins and needles.
• Macroglossia: an enlarged tongue, a typical (even more uncommon) appearance of the AL variant.

Causes and Risk Factors

The causes of cardiac amyloidosis are rooted in the biology of protein folding. The body consists of the building blocks, which are proteins, and to do their work properly, they are required to be folded into particular three-dimensional structures. Once they become misfolded, they may become insoluble and sticky to create the fibres that define this disease.

Genetic and Hereditary Factors

With Hereditary ATTR (hATTR), the mutation in the TTR gene causes the condition. This is an autosomal dominant condition, meaning just one copy of the faulty gene is enough to cause the disease. Each child of an affected parent has a 50% chance of inheriting the mutation. Certain mutations are significantly more prevalent in specific populations; for example, the V122I mutation is found at a notably higher frequency in people of African or Caribbean descent, making awareness in these communities particularly important.

Environmental Triggers and Ageing

In this form, there is no inherited genetic fault. Instead, the TTR protein simply becomes less chemically stable as a natural consequence of ageing, and progressively misfolds into amyloid fibrils over many decades. This is why wild-type ATTR is predominantly diagnosed in men over the age of 65. It is thought to be far more common than previously recognised, and many cases may still go undiagnosed.

Current Treatment Options and Management

While cardiac amyloidosis was once considered a terminal diagnosis with few options, the last decade has seen a revolution in treatment. The treatment is two-fold: to control the symptoms of heart failure and prevent the formation of new amyloid fibrils.

Symptom Management of Heart Failure

The major objective is to maintain the comfort of the patient and minimise the fluid overload. This is normally attained by:

• Diuretics: Drugs which are used to assist the body in getting rid of excess salt and water in the form of urine.
• Sodium Restriction: A low-sodium diet is essential to ensure that there is no fluid retention.
• Close Monitoring of the Medicine: The usual heart failure medications, such as ACE inhibitors or Beta-blockers, are poorly tolerated among patients with the amyloidosis condition, as their hearts use a faster heart rate to sustain performance.

Conclusion

Cardiac amyloidosis is a sophisticated and often hidden cause of heart failure. Although the systematic obstacles of the stiff heart prove to be quite powerful, the introduction of non-invasive diagnostics and specific protein therapies has provided a new hope to thousands of people. The most significant aspect of maintaining heart activity and prolonging life is early diagnosis. The ability to notice the red flags, i.e., carpal tunnel syndrome coupled with breathlessness, will help make the diagnosis faster and more efficient and provide a more efficient treatment strategy.

In the journey of managing a chronic and complex condition like cardiac amyloidosis, financial peace of mind is just as important as medical care. Niva Bupa NRI Health Insurance provides a range of special plans that will cater to the current treatment and critical illnesses, giving a safety net to the families that have to deal with the high prices of special cardiac medication and extended hospital stays. Niva Bupa will also make sure that you stick to the recovery and a heart-healthy lifestyle with their emphasis on customer-centric claims and their overall wellness support.

FAQs

1. What causes cardiac amyloidosis?

This condition has an underlying cause, which is the deposition of abnormal and misfolded proteins (formed as fibrils) within the extracellular space of the heart muscle. These proteins can not keep their proper three-dimensional shape, and thus, they become insoluble and sticky, and due to this, they cause their buildup in the myocardium. In light chain (AL) amyloidosis, the pathogenesis is a plasma cell disorder in which the marrow is producing inappropriate proteins. The TTR protein, which is produced by the liver in transthyretin (ATTR) amyloidosis, becomes unstable, which in the hereditary version is a genetic mutation, whereas in the wild-type version is caused by age.

2. What are warning signs of amyloidosis?

Symptoms of progressive heart failure, in the form of warning signs, are usually witnessed because the heart becomes more rigid. Excessively noticing the shortness of breath during physical activity or in the lying flat position, sustained fatigue and lethargy due to the inability of the heart to pump enough oxygenated blood are also common indicators. Ankle swelling, foot swelling, and leg swelling are very common symptoms due to fluid accumulation. In addition to the symptoms involving the heart, such warning signs as tingling or numbness of the hands and feet, an enlarged tongue, or a history of carpal tunnel syndrome in both wrists can be present.

3. Is cardiac amyloidosis fatal?

While cardiac amyloidosis is a serious and potentially life-threatening condition, it is no longer considered a definitive terminal diagnosis. In the past, there were no treatments and limited treatments; hence, the prognosis used to be poor. But with modern medicine, specific treatments have been developed which can either stabilise the proteins or prevent protein production entirely and life expectancy and the quality of life are greatly enhanced. The form of amyloidosis and the early diagnosis and treatment of the condition are also determinants of the outcome.

4. What is the red flag for cardiac amyloidosis?

An evident warning sign of this disorder is the heart failure manifestations along with the non-cardiac specific problems. Specifically, the history of bilateral carpal tunnel syndrome several years before the introduction of heart symptoms is a key warning sign of the transthyretin (ATTR) variant. Other major red flags are spontaneous rupture of bicep tendons without any form of trauma and spinal stenosis. When these systemic issues appear alongside unexplained thickening of the heart walls on an echocardiogram, clinicians strongly suspect cardiac amyloidosis.